Nan Yang

Nan Yang

Auto-generated profile, based on publicly available information

Nan Yang

Department of Pharmacy The Third Xiangya Hospital of Central South University Changsha China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2026 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
SZShengnan Zhang
Shengnan Zhang
NYNan Yang
Nan Yang
RYRuwei Yang
Ruwei Yang
YQYuanfang Qin
Yuanfang Qin
TWTingting Wu
Tingting Wu
QPQi Pei
Qi Pei
Intravenous polymyxin B (PMB) is widely used for treating drug‐resistant gram‐negative pneumonia, though its efficacy in pulmonary infections is considered limited. This study aims to identify patients with severe pulmonary infections suitable for treatment with intravenous PMB alone and to recommend individualized optimal dosing regimens. Physiologically based pharmacokinetic (PBPK) models, developed using data from mice, healthy subjects, and critically ill patients, were employed to predict PMB concentrations in epithelial lining fluid (ELF) and plasma. All models were validated against published pharmacokinetic data, and Monte Carlo simulations were used to evaluate various dosing regimens. The therapeutic target was defined as an ELF steady‐state 24 h area under the concentration‐time curve to minimum inhibitory concentration (AUC ss,24h /MIC) ≥ 50. Simulations showed that intravenous PMB maintenance regimens of 100 mg, 1.25 mg/kg, or 1.50 mg/kg q12h enabled 94.4%, 82.2%, and 93.5% of critically ill patients to achieve the ELF pharmacokinetic/pharmacodynamic (PK/PD) target for pathogens with an MIC of 1 mg/L. A plasma AUC ss,24h /MIC threshold of 80.6 was identified as an alternative PK/PD target, with retrospective analysis confirming significantly better outcomes for patients exceeding this threshold ( p = 0.038), warranting prospective validation. Overall, PBPK modeling supports 100 mg or 1.50 mg/kg q12h as candidate initial intravenous regimens for critically ill patients with pulmonary infections. Dosing adjustments based on MIC and plasma AUC ss,24h /MIC value are recommended. Adjunctive nebulization or combination therapy is advised for MICs ≥ 2 mg/L, while 50 mg q12h is sufficient for MICs ≤ 0.5 mg/L. Plasma AUC ss,24h /MIC values exceeding 80.6 may guide individualized dosing when therapeutic drug monitoring is available.